PFIZER Pharmaceuticals has
struck a deal with King
Pharmaceuticals to acquire the
latter for US$3.6 billion.
The move represents a 40% per
share premium on King’s closing
share price at the start of the week.
According to Pfizer the deal is set
to shore up its earnings in the wake
of Lipitor, the world’s best selling
cholesterol treatment, losing its
patent in late 2011.
King Pharmaceuticals has a drug
portfolio incl. Altace, Skelaxin,
Levoxyl, Embeda, Acurox and RemoxyThe above article was sent to subscribers in Pharmacy Daily's issue from 13 Oct 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Oct 10
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.